Net Income (Loss) Attributable to Parent of BriaCell Therapeutics Corp. from 31 Jul 2021 to 31 Jan 2026

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
BriaCell Therapeutics Corp. quarterly and annual Net Income (Loss) Attributable to Parent in USD history and change rate from 31 Jul 2021 to 31 Jan 2026.
  • BriaCell Therapeutics Corp. Net Income (Loss) Attributable to Parent for the quarter ending 31 Jan 2026 was $7,221,820, a 15% decline year-over-year.
  • BriaCell Therapeutics Corp. Net Income (Loss) Attributable to Parent for the twelve months ending 31 Jan 2026 was $29,637,657, a 156% decline year-over-year.
  • BriaCell Therapeutics Corp. annual Net Income (Loss) Attributable to Parent for 2025 was $26,311,867, a 449% decline from 2024.
  • BriaCell Therapeutics Corp. annual Net Income (Loss) Attributable to Parent for 2024 was $4,791,466, a 76% increase from 2023.
  • BriaCell Therapeutics Corp. annual Net Income (Loss) Attributable to Parent for 2023 was $20,302,394, a 24% increase from 2022.
Source SEC data
View on sec.gov
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

BriaCell Therapeutics Corp. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $29,637,657 $7,221,820 -$930,400 -15% 01 Nov 2025 31 Jan 2026 10-Q 10 Mar 2026 2026 Q2
Q3 2025 $28,707,257 $8,197,565 -$2,395,390 -41% 01 Aug 2025 31 Oct 2025 10-Q 11 Dec 2025 2026 Q1
Q2 2025 $26,311,867 $8,091,370 -$6,877,205 -566% 01 May 2025 31 Jul 2025 10-K 16 Oct 2025 2025 FY
Q1 2025 $19,434,662 $6,126,902 -$7,842,661 -457% 01 Feb 2025 30 Apr 2025 10-Q 16 Jun 2025 2025 Q3
Q4 2024 $11,592,001 $6,291,420 +$5,003,183 +44% 01 Nov 2024 31 Jan 2025 10-Q 10 Mar 2026 2026 Q2
Q3 2024 $16,595,184 $5,802,175 -$11,803,718 -197% 01 Aug 2024 31 Oct 2024 10-Q 11 Dec 2025 2026 Q1
Q2 2024 $4,791,466 $1,214,165 +$1,204,490 +50% 01 May 2024 31 Jul 2024 10-K 16 Oct 2025 2025 FY
Q1 2024 $5,995,956 $1,715,759 +$6,611,195 01 Feb 2024 30 Apr 2024 10-Q 16 Jun 2025 2025 Q3
Q4 2023 $12,607,151 $11,294,603 +$587,159 +4.9% 01 Nov 2023 31 Jan 2024 10-Q 12 Mar 2025 2025 Q2
Q3 2023 $13,194,310 $6,001,543 +$7,108,084 01 Aug 2023 31 Oct 2023 10-Q 16 Dec 2024 2025 Q1
Q2 2023 $20,302,394 $2,418,655 -$1,968,303 -437% 01 May 2023 31 Jul 2023 10-K 29 Oct 2024 2024 FY
Q1 2023 $18,334,091 $4,895,436 +$5,120,137 +51% 01 Feb 2023 30 Apr 2023 10-Q 14 Jun 2024 2024 Q3
Q4 2022 $23,454,228 $11,881,762 -$23,042,269 -206% 01 Nov 2022 31 Jan 2023 10-Q 18 Mar 2024 2024 Q2
Q3 2022 $411,959 $1,106,541 +$26,426,944 +96% 01 Aug 2022 31 Oct 2022 10-Q 14 Dec 2023 2024 Q1
Q2 2022 $26,838,903 $450,352 01 May 2022 31 Jul 2022 10-K 25 Oct 2023 2023 FY
Q1 2022 $10,015,573 01 Feb 2022 30 Apr 2022 10-Q 14 Jun 2023 2023 Q3
Q4 2021 $11,160,507 01 Nov 2021 31 Jan 2022 10-Q 16 Mar 2023 2023 Q2
Q3 2021 $27,533,485 01 Aug 2021 31 Oct 2021 10-Q 14 Dec 2022 2023 Q1

BriaCell Therapeutics Corp. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $26,311,867 -$21,520,401 -449% 01 Aug 2024 31 Jul 2025 10-K 16 Oct 2025 2025 FY
2024 $4,791,466 +$15,510,928 +76% 01 Aug 2023 31 Jul 2024 10-K 16 Oct 2025 2025 FY
2023 $20,302,394 +$6,536,509 +24% 01 Aug 2022 31 Jul 2023 10-K 29 Oct 2024 2024 FY
2022 $26,838,903 -$13,022,703 -94% 01 Aug 2021 31 Jul 2022 10-K 25 Oct 2023 2023 FY
2021 $13,816,200 01 Aug 2020 31 Jul 2021 10-K 28 Oct 2022 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.